CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer - Concepedia

Concepedia

Publication | Open Access

CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer

DOI Full Paper Access

41

Citations

36

References

2022

Year

Geny Piro, Carmine Carbone, Antonio Agostini, Annachiara Esposito, Maria De Pizzol, Rubina Novelli, Marcello Allegretti, Andrea Aramini, Alessia Caggiano, Alessia Granitto,

British Journal of Cancer

OncologyCxcr1/2 Dual-inhibitor LadarixinPancreatic CancerMedicineImmunologyImmune Checkpoint InhibitorCancer BiologyRadiation OncologyTumour Burden

References

	Year	Citations

Page 1

Page 1